PIPELINE

With over a decade of advanced research and development, American Gene Technologies™ (AGT), has built a broad, robust gene delivery platform that accelerates the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications to complex diseases. AGT has an extensive and growing patent portfolio protecting its lentiviral vector and proprietary process for generating autologous cell products that treat HIV as well as its methods and Composition for the Activation of Gamma Delta T cells to kill solid cancer tumors.

Using its platform and patented methods, AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer.

AGT103-T, our HIV therapeutic, is currently in Phase 1 clinical trials, and we expect to see the lead candidates in our Immuno-oncology and Phenylketonuria(PKU) programs move into the clinic in the next few years as well.

HIV CURE PROGRAM

  • Granted 3 USPTO patents to protect its lentiviral vector and proprietary process for generating autologous cell products for treating HIV (“HIV Pre-Immunization and Therapy”)
  • Signed Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy
  • Former scientific advisor, Robert R. Redfield, M.D., was appointed Director of the Centers for Disease Control and Prevention (CDC)
  • Completed process development for the AGT103-T automated cell manufacturing protocol; the GMP vector for the HIV cure program was completed.
  • Selected University of Maryland, Baltimore (UMB) as the new clinical site for its non-IND study, AGT-CS168, to collect sample venous blood specimens from HIV positive individuals

IMMUNO-ONCOLOGY

  • Granted 8 USPTO patents to protect its lead asset in immunotherapy for cancer (“Methods and Composition for the Activation of Gamma Delta T cells”)
  • Launched Oncology Science Advisory Group (OSAG) of globally recognized scientists to accelerate its immuno-oncology cancer cure program

Phenylketonuria (PKU)

USPTO Patents & FDA Designation

AGT’s patent portfolio protects its technology platform and methods. In addition to below, AGT has several patents pending and over 20 patent families represented by filings with the USPTO and international patent offices. Also, AGT has been granted FDA Orphan Drug Designation for its treatment of Phenylketonuria (PKU).

Scientific & Clinical Advisors